A policy research center at Penn focused on public communication, democracy, and policy impact.
Moderna has won FDA approval for its mRNA flu vaccine mFlusiva for adults 50–64 and accelerated approval for those 65 and older. The decision follows a contentious review earlier this year, a unanimous advisory panel recommendation in June and political disputes inside US health agencies over mRNA vaccines. Retail availability is expected in coming weeks.
Voter pressure is reshaping the AI buildout as governors reimpose restrictions, audit projects, and strike new guardrails. Public opinion shows broad opposition to new data centers, with political consequences across several states.